Researchers from Yale Cancer Center identified the Cancer and Aging Research Group calculator as an effective tool in assessing chemotherapy toxicity probability in geriatric patients.
A pilot program developed by researchers at Yale Cancer Center offering next day access for oncologic consultation for patients showed reduced wait times for initial access to cancer care and increased patient satisfaction, according to a new report.Â
The FDA granted 510(k) clearance to the Dayspring Lite treatment for lymphedema and venous disease.Â
The FDA granted Breakthrough Device designation to the Novilase Interstitial Laser System and its proposed indication for use: the focal destruction of malignant breast tumors in adult women seeking a breast conserving procedure.
The FDA granted Fast Track designation to Acelarin (NUC-1031), currently being evaluated in a phase III study, NuTide:121, for the first-line treatment of patients with advanced biliary tract cancer.Â
The FDA accepted for priority review the supplemental Biologics License Application for PD-1 inhibitor Libtayo (cemiplimab-rwlc), a monoclonal antibody, to treat patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.Â
The FDA issued a draft guidance, Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products.
MD Anderson Cancer Center and BostonGene Corporation formed a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures.
On Dec. 8, 2020, a month after losing the election, then-president Donald Trump announced his intent to name 26 people to advisory boards across the federal government. Among them were three would-be members of the National Cancer Advisory Board, and in the months following, these three appointments—which have been blocked and ultimately terminated by the... […]
In early 2020, telehealth was a hot new trend in patient care, but with utilization sporadic and episodic at best, providers were generally skeptical as to whether this virtual technique of delivering care was a viable option for advanced clinical services, especially in oncology.
